Aberdeen Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Aberdeen Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$6.62M	Sell	13,472 -1,045	-7%	-$457K	0.02%	419
2017 Q1	$5.63M	Buy	14,517 +1,354	+10%	+$502K	0.02%	436
2016 Q4	$4.83M	Sell	13,163 -946	-7%	-$360K	0.02%	445
2016 Q3	$5.67M	Sell	14,109 -290	-2%	-$116K	0.02%	416
2016 Q2	$5.03M	Sell	14,399 -1,627	-10%	-$627K	0.02%	420
2016 Q1	$5.78M	Sell	16,026 -3,404	-18%	-$1.4M	0.02%	391
2015 Q4	$10.2M	Buy	19,430 +2,666	+16%	+$1.44M	0.03%	291
2015 Q3	$7.8M	Sell	16,764 -1,079	-6%	-$579K	0.03%	305
2015 Q2	$9.1M	Sell	17,843 -953	-5%	-$465K	0.03%	280
2015 Q1	$8.49M	Sell	18,796 -14,088	-43%	-$5.97M	0.02%	279
2014 Q4	$13.5M	Sell	32,884 -17,537	-35%	-$6.9M	0.03%	228
2014 Q3	$18.2M	Buy	50,421 +20,488	+68%	+$6.87M	0.04%	222
2014 Q2	$8.46M	Buy	29,933 +21,533	+256%	+$6.38M	0.02%	359
2014 Q1	$2.52M	Hold	8,400	–	–	0.01%	301
2013 Q4	$2.29M	Hold	8,400	–	–	0.01%	290
2013 Q3	$2.63M	Sell	8,400 -200	-2%	-$52.6K	0.01%	251
2013 Q2	$1.93M	Buy	+8,600	New	+$2M	0.01%	304

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Aberdeen Asset Management's REGN Position: Q2 2017 in Review

Aberdeen Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 7.2% in Q2 2017, selling an estimated $457K and leaving 13,472 shares worth $6.62M. The position accounts for 0.02% of the portfolio, ranked #419.

Aberdeen Asset Management first reported a position in REGN in Q2 2013 and has held it in 17 quarters since. The position peaked at $18.2M in Q3 2014. 604 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

Aberdeen Asset Management held 13,472 shares of Regeneron Pharmaceuticals worth $6.62M as of Q2 2017.
Aberdeen Asset Management sold 1,045 Regeneron Pharmaceuticals shares in Q2 2017, an estimated $457K.
Regeneron Pharmaceuticals made up 0.02% of Aberdeen Asset Management's portfolio in Q2 2017, its #419 holding.
Aberdeen Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Aberdeen Asset Management's Regeneron Pharmaceuticals position peaked at $18.2M in Q3 2014.
604 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.